Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects

NCT01913028 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01913028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01913028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
January 31, 2014
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy